临床试验登记· University of Michigan Rogel Cancer Center · ClinicalTrials.gov·· 10 小时前评分31
Natalizumab预防CAR T细胞治疗后ICANS：复发或难治性DLBCL或MCL患者的2期临床试验
Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell Therapy
导读
NCT07892027 2期试验将评估Natalizumab预防CAR T细胞治疗后ICANS的效果，计划入组26人。该试验由University of Michigan Rogel Cancer Center申办，纳入复发或难治性DLBCL或MCL患者，状态为RECRUITING。
来源：临床试验登记 · clinicaltrials.gov